54013-91-1

Basic information

• Product Name: Piperazine, 1-[2-(1-methylethoxy)phenyl]-
• CAS NO: 54013-91-1
• Molecular Formula: C13H20N2O
• Molecular Weight: 220.315
• Mol File: 54013-91-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-[2-(1-methylethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-[2-(1-methylethoxy)phenyl]-(54013-91-1)
• EPA Substance Registry System: Piperazine, 1-[2-(1-methylethoxy)phenyl]-(54013-91-1)

Safety Data

• Hazardous Substances Data: 54013-91-1(Hazardous Substances Data)

Upstream product

• 29026-74-2 2-isopropoxy-phenylamine 
• 119695-87-3 fumarate salt of 4-(2-isopropyloxyphenyl)piperazine 
• 110-85-0 piperazine 
• 701-07-5 1-bromo-2-isopropoxybenzene 

Downstream Products

• 137966-12-2 1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-azocan-2-one 
• 137966-04-2 1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-azepan-2-one 
• 123547-30-8 RWJ 25730 
• 123547-35-3 1-[[5-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-1H-pyrrol-2-yl]methyl]-2-piperidinone 
• 137965-79-8 1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-pyrrolidin-2-one 
• 148888-30-6 3-[1-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]benzonitrile 
• 154060-72-7 1-<<3-(acetoxymethyl)phenyl>methyl>-4-<2-(1-methylethoxy)phenyl>piperazine 

Relevant articles and documents

SUBSTITUTED ISOINDOLE-1,3-DIONES

The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower

CYCLOHEXYLDIAMINES AS SELECTIVE ALPHA 1A/1D ADRENORECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATE HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS

The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable form thereof, as dual selective a1a / a 1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

Synthesis and Structure-Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (Ki = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (Ki = 6600 nM). Sulfonamide 39 (Ki = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (Ki = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (Ki = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.